The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor

PLoS One. 2013 May 3;8(5):e62895. doi: 10.1371/journal.pone.0062895. Print 2013.

Abstract

The glucocorticoid receptor (GR) regulates several physiological functions, including immune function and apoptosis. The HIV-1 virus accessory protein, viral protein R (Vpr), can modulate the transcriptional response of the GR. Glucocorticoids (GCs) and Vpr have been reported to induce apoptosis in various cells, including T-cells. We have previously shown that the injectable contraceptive, medroxyprogesterone acetate (MPA) is a partial to full agonist for the GR, unlike norethisterone acetate (NET-A). We investigated the functional cross talk between the GR and Vpr in inducing apoptosis in CD4(+) T-cells, in the absence and presence of GCs and these progestins, as well as progesterone. By using flow cytometry, we show that, in contrast to NET-A and progesterone, the synthetic GR ligand dexamethasone (Dex), cortisol and MPA induce apoptosis in primary CD4(+) T-cells. Furthermore, the C-terminal part of the Vpr peptide, or HIV-1 pseudovirus, together with Dex or MPA further increased the apoptotic phenotype, unlike NET-A and progesterone. By a combination of Western blotting, PCR and the use of receptor- selective agonists, we provide evidence that the GR and the estrogen receptor are the only steroid receptors expressed in peripheral blood mononuclear cells. These results, together with the findings that RU486, a GR antagonist, prevents Dex-, MPA- and Vpr-mediated apoptosis, provide evidence for the first time that GR agonists or partial agonists increase apoptosis in primary CD4(+) T-cells via the GR. We show that apoptotic induction involves differential expression of key apoptotic genes by both Vpr and GCs/MPA. This work suggests that contraceptive doses of MPA but not NET-A or physiological doses of progesterone could potentially accelerate depletion of CD4(+) T-cells in a GR-dependent fashion in HIV-1 positive women, thereby contributing to immunodeficiency. The results imply that choice of progestin used in contraception may be critical to susceptibility and progression of diseases such as HIV-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Apoptosis
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / drug effects*
  • CD4-Positive T-Lymphocytes / metabolism
  • Cells, Cultured
  • Contraceptive Agents, Female / pharmacology*
  • Dexamethasone / pharmacology
  • Gene Expression Regulation
  • Gene Products, vpr / pharmacology*
  • HIV-1 / chemistry*
  • Humans
  • Hydrocortisone / pharmacology
  • Medroxyprogesterone Acetate / pharmacology*
  • Mifepristone / pharmacology
  • Molecular Sequence Data
  • Norethindrone / analogs & derivatives*
  • Norethindrone / pharmacology
  • Norethindrone Acetate
  • Progesterone / pharmacology
  • Receptors, Estrogen / genetics
  • Receptors, Estrogen / metabolism
  • Receptors, Glucocorticoid / antagonists & inhibitors
  • Receptors, Glucocorticoid / genetics*
  • Receptors, Glucocorticoid / metabolism
  • Signal Transduction

Substances

  • Contraceptive Agents, Female
  • Gene Products, vpr
  • Receptors, Estrogen
  • Receptors, Glucocorticoid
  • Mifepristone
  • Progesterone
  • Dexamethasone
  • Norethindrone Acetate
  • Medroxyprogesterone Acetate
  • Norethindrone
  • Hydrocortisone

Grants and funding

This work was funded by LIFElab (www.lifelab.org.za) with funds from the South African Government’s Department of Science and Technology, under the SHARP program (South African HIV/AIDS Research and Innovation Platform) by a grant to JPH. Thanks is given to the Claude Leon Foundation for postdoctoral funding to MT, as well as the Carnegie corporation for post-doctoral funding to CA and PhD funding to RMR. RMR was also funded by the National Research Foundation. ADT was supported by scholarships from the National Research Foundations (NRF) and the Poliomyelitis Research Foundation (PRF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.